Roche Reports Updated POLARIX Trial Data for Polivy in First-Line DLBCL

Roche today presented updated data from the Phase 3 POLARIX trial evaluating Polivy (polatuzumab vedotin-piiq) plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The updated data showed that the progression-free survival benefit of Polivy plus R-CHP over R-CHOP was maintained at three years.